Dev Information Technology Limited has informed the Exchange regarding a press release dated July 02, 2025, titled "Dev IT Secures Major ₹ 4.4 Cr IT Deal with Alivus Lifesciences .".
DEVIT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dev Information Technology Limited (DEVIT) has secured orders worth approximately ₹4.4 crore from Alivus Lifesciences Limited, a pharmaceutical sector client. The engagement includes a ₹3.60 crore order for Microsoft Select Plus perpetual licenses, where DEVIT played an advisory role in aligning IT infrastructure with the right licensing model, and a direct ₹80 lakh order for enterprise software solutions covering Microsoft, Zoho, Adobe, and TeamViewer products. The company highlighted that these wins strengthen its positioning as a trusted IT partner in the high-growth pharmaceutical sector. Management also noted meaningful traction in the government sector, adding further depth to its portfolio. For context, in consolidated FY25, the company reported Total Income of ₹1,839.09 million, EBITDA of ₹237.18 million, and Net Profit of ₹147.80 million, making this a relatively modest order at roughly 2.4% of annual revenue.
Positive but small-scale: the order reinforces DEVIT's enterprise IT capabilities and pharma-sector credibility, though the ₹4.4 crore size is modest relative to its ₹184 crore FY25 revenue, so a meaningful stock price reaction is unlikely unless more such deals follow.